1
|
Delbaldo C, Serin D, Mousseau M, Greget S, Audhuy B, Priou F, Berdah JF, Teissier E, Laplaige P, Zelek L, Quinaux E, Buyse M, Piedbois P. A phase III adjuvant randomised trial of 6 cycles of 5-fluorouracil-epirubicine-cyclophosphamide (FEC100) versus 4 FEC 100 followed by 4 Taxol (FEC-T) in node positive breast cancer patients (Trial B2000). Eur J Cancer 2013; 50:23-30. [PMID: 24183460 DOI: 10.1016/j.ejca.2013.09.023] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2013] [Revised: 08/16/2013] [Accepted: 09/26/2013] [Indexed: 11/25/2022]
Abstract
BACKGROUND Standard adjuvant chemotherapy regimens for patients with node positive (N+) breast cancer consisted of anthracycline followed by taxane. The European Association for Research in Oncology embarked in 2000 on a phase III trial comparing 6 cycles of FEC100 versus 4 FEC100 followed by 4 Taxol. Primary end-point was disease free survival. Secondary end-points were overall survival, local recurrence free interval, metastases free interval and safety. PATIENTS AND METHODS Between March 2000 and December 2002, 837 patients were randomised between 6FEC100 for 6 cycles (417patients) or FEC100 for 4 cycles then Taxol 175mg/m(2)/3 weeks for 4 cycles (4FEC100-4T) (420 patients). One thousand patients had been planned initially but the trial was closed earlier due to slow accrual. RESULTS Hazard ratios (HRs) were 0.99 for disease-free survival (DFS) (95%CI: 0.77-1.26; p=0.91), and 0.85 for overall survival (OS) (95%CI: 0.62-1.15; p=0.29). Nine-year DFS were 62.9% versus 62.5% for 6FEC100 and 4FEC100-4T, respectively. Nine-year OS were 73.9% versus 77% for 6FEC100 and 4FEC100-4T, respectively. Toxicity analyses based on 803 evaluable patients showed that overall grade 3-4 toxicities were similar in both arms (63% versus 58% for 6FEC100 arm and 4FEC100-4T arm, respectively; p=0.16). CONCLUSION In this trial replacing the last 2 FEC100 cycles of 6FEC100 regimen by 4 Taxol does not lead to a discernable DFS or OS advantage. The lack of a significant difference between the randomised treatment arms may however be due to a lack of power of this trial to detect small, yet clinically worthwhile, treatment benefits.
Collapse
Affiliation(s)
- C Delbaldo
- Service de Cancérologie, Groupe Hospitalier Diaconesses Croix Saint Simon, Paris, France.
| | - D Serin
- Clinique St Catherine, Avignon, France
| | | | - S Greget
- Clinique St Clotilde, La Réunion, France
| | | | - F Priou
- Service Onco-Hématologie, Centre Hospitalier Départemental, La Roche Sur Yon, France
| | | | - E Teissier
- Centre Azuréen de Cancérologie, Mougins, France
| | - P Laplaige
- Polyclinique de Blois, La Chaussée St Victor, France
| | - L Zelek
- Service de Cancérologie, Hôpital Avicennes, Hôpitaux Universitaires Paris-Seine-Saint Denis, France
| | - E Quinaux
- International Development Drug Institute (IDDI), Louvain-la-Neuve, Belgium
| | - M Buyse
- International Development Drug Institute (IDDI), Louvain-la-Neuve, Belgium
| | - P Piedbois
- Service d'Oncologie Médicale, Hôpital Henri Mondor, Créteil, France
| | | |
Collapse
|
2
|
Natale R, Gada C, Ronchin P, Kreitmann T, Reix C, Simonnot E, Miélot P, Teissier E. Un recalage quotidien sur repères fiduciels améliore la conformité de la radiothérapie prostatique par rapport à un recalage osseux. Cancer Radiother 2013. [DOI: 10.1016/j.canrad.2013.06.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
3
|
Moureau-Zabotto L, Resbeut M, Gal J, Mineur L, Teissier E, Hebuterne X, Muyldermans P, Francois E, Chamorey E, Gerard JP. Management and clinical outcome of rectal cancer in patients ≥80 years treated in southern France (PACA region) between 2006 and 2008. J Surg Oncol 2013; 108:450-6. [DOI: 10.1002/jso.23428] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2013] [Accepted: 08/10/2013] [Indexed: 11/11/2022]
Affiliation(s)
| | - M. Resbeut
- Departement de Radiotherapie; Institut Paoli Calmettes; France
- Croix Rouge Francaise, Centre de Radiothérapie Saint Louis; Toulon France
| | - J. Gal
- Centre Antoine Lacassagne; Nice France
| | - L. Mineur
- Institut Sainte Catherine; Avignon France
| | - E. Teissier
- Centre Azureen de Cancérologie; Mougins France
| | | | - P. Muyldermans
- Centre de Radiotherapie du Pays d'Aix; Aix-en-Provence France
| | | | | | | |
Collapse
|
4
|
Zaccariotto A, Tallet A, Maingon P, Lemanski C, Guerder C, Teissier E, Bourgier C, Conte M, Cowen D. Triple Negative Breast Cancer: Which Factors Predict for Local Recurrence? A Study of the CORS Group. Int J Radiat Oncol Biol Phys 2012. [DOI: 10.1016/j.ijrobp.2012.07.367] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
5
|
Dubergé T, Bénézery K, Resbeut M, Azria D, Minsat M, Ellis S, Teissier E, Zaccariotto A, Champetier C, Cowen D. [Adenoid cystic carcinoma of the head and neck: a retrospective series of 169 cases]. Cancer Radiother 2012; 16:247-56. [PMID: 22652299 DOI: 10.1016/j.canrad.2012.02.003] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/04/2011] [Revised: 02/20/2012] [Accepted: 02/27/2012] [Indexed: 10/28/2022]
Abstract
PURPOSE Adenoid cystic carcinoma represents 1% of head and neck cancers. Adenoid cystic carcinomas are slow growing tumours with high potential for local recurrence. Treatment usually associates radiotherapy and surgery, but the role of radiotherapy remains unclear. We report a retrospective multicentric study of the management and prognostic factors of 169 adenoid cystic carcinomas of head and neck. PATIENTS AND METHODS Between 1982 and 2010, 169 patients with adenoid cystic carcinoma of the head and neck were referred to the Cercle des oncologues radiothérapeutes du Sud departments of radiotherapy either for primary untreated tumour (n=135) or for a recurrence of previously treated tumour (n=34). The site of adenoid cystic carcinoma was: parotid gland (n=48, 28.4%), minor salivary gland (n=35, 20.7%), submandibular gland (n=22, 13%), sinus cavities (n=22, 13%), other (n=42, 24.9%). Tumour stages were: T1 (12.4%); T2 (14.2%); T3 (12.4%); T4 (41.4%) and Tx (19.5%). Lymph node involvement was 13% and distant metastasis 8.9%. For adenoid cystic carcinomas of the parotid gland, major nerve involvement was evaluated. Preferential site of metastasis was the lung (87.5%). Treatments were: surgery alone (n=27), surgery and adjuvant radiotherapy (n=89), surgery and adjuvant chemoradiotherapy (n=12), exclusive chemoradiotherapy (n=13), exclusive radiotherapy (n=14), other associations (n=5) and no treatment (n=7). Radiotherapy was delivered through photons (n=119), neutrons (n=6), both (n=4). Two patients had a brachytherapy boost. Median prescribed doses to T and N were respectively 65 Gy and 50 Gy for the 119 photons treated patients. RESULTS Mean follow-up was 58 months (range 1-250 months). As of December 1, 2010, 83 patients were alive with no evolutive disease (49%), 35 alive and had recurred, 18 had uncontrolled evolutive disease, 28 had died of adenoid cystic carcinoma and 5 of intercurrent disease. Overall survival and disease free survival were respectively 72% and 72% at 5 years, 53% and 32% at 10 years; 5 and 10-year freedom from local recurrence were 81% and 52% respectively. Nerve involvement was found in 17/48 parotid gland adenoid cystic carcinomas. The Cox model including all patients, showed that surgery (P<0.001), surgical margins (P=0.015), nerve involvement (P=0.0079), length of radiotherapy (P=0.018), and tumour location (P=0.041) were associated with disease free survival. CONCLUSION In this large series of adenoid cystic carcinoma of head and neck with a majority of T3-T4 tumours, 10-year survivals were achieved for 50% of patients. Radiotherapy did not impact survival.
Collapse
Affiliation(s)
- T Dubergé
- Service de radiothérapie, hôpital de la Timone adultes, Marseille, France.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Cowen D, Duberger T, Hannoun-Levi J, Azria D, Salem N, Ellis S, Teissier E, Resbeut M. Adenoid Cystic Carcinoma Of The Head and Neck: Retrospective Series Of 169 Cases. Int J Radiat Oncol Biol Phys 2011. [DOI: 10.1016/j.ijrobp.2011.06.807] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
7
|
Gross E, Hannoun-Levi JM, Rouanet P, Houvenaeghel G, Teissier E, Ellis S, Resbeut M, Tallet A, Vaini Cowen V, Azria D, Cowen D. [Evaluation of immediate breast reconstruction and radiotherapy: factors associated with complications]. Cancer Radiother 2010; 14:704-10. [PMID: 20674442 DOI: 10.1016/j.canrad.2010.05.004] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2009] [Revised: 05/01/2010] [Accepted: 05/12/2010] [Indexed: 10/19/2022]
Abstract
OBJECTIVES To determine prospectively the factors associated with reconstruction failure (i.e. requiring expander removal) and capsular contracture in patients undergoing mastectomy and immediate two-stage breast reconstruction with a tissue expander and implant, and radiotherapy for breast cancer. This is a multi-institutional prospective nonrandomized trial. PATIENTS AND METHODS Between 2/1998 and 9/2006, we prospectively evaluated 141 consecutive patients who received 141 implants after mastectomy and underwent chest wall radiotherapy (46 to 50 Gy in 23 to 25 fractions). Patients were evaluated after 24 to 36 months by two senior physicians (radiation oncologist and surgeon). RESULTS Medical follow-up was 37 months. Baker 1 and 2 capsular contracture was observed in 67.5% of patients, Baker 3 and 4 in 32.5%. There were 32 reconstruction failures. In a univariate analysis, the following factors were associated with Baker 3 and 4 capsular contracture: surgeon, use of hormonotherapy and smoking, of which only one remained in the multivariate analysis: surgeon. In a univariate analysis, the following factors were associated with reconstruction failure: tumor size T3 or T4, smoking, pN+ axilla. Three factors remained associated with reconstruction failure in a multiple logistic regression: large tumors T3/T4, smoking and pN+ axilla. CONCLUSIONS Mastectomy, radiotherapy and immediate breast reconstruction with a tissue expander and implant should be considered when breast conserving surgery has been denied. Adequate patients can be easily selected by using three factors of favourable outcome.
Collapse
Affiliation(s)
- E Gross
- Département de radiothérapie, hôpital de la Timone, rue Saint-Pierre, 13005 Marseille, France.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Delbaldo C, Serin D, Priou F, Laplaige P, Greget S, Angellier E, Teissier E, Berdah J, Fabbro M, Quinaux E. Analysis of the impact of growth factor on the haematological safety of dose-dense regimen in the randomized phase II adjuvant trial BO3. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.605] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
605 Background: In a randomized phase II study, P. Piedbois et al. explored a dose-dense docetaxel (T) followed by epirubicin/cyclophosphamide (EC) every two weeks versus the reverse sequence, versus standard-dose docetaxel, epiribucin and cyclophosphamide (TEC) every 3 weeks. The main purpose of this second analysis was to further explore the haematological safety of each regimen in patients receiving primary prophylactic pegfilgrastim. Methods: One hundred patients with node-positive invasive breast adenocarcinoma were randomized between (arm A) docetaxel 75 mg/m2, epiribucin 75 mg/m2 and cyclophosphamide 500 mg/m2 (TEC) every 3 weeks for 6 cycles (35 patients) or (arm B) epiribucin 100 mg/m2 and cyclophosphamide 600 mg/m2 every 2 weeks for 4 cycles, followed by T 100 mg/m2 (EC→T) every 2 weeks for 4 cycles (31 patients) or (arm C) T→ EC (34 patients). Among the 99 patients who received chemotherapy, 79 received pegfilgrastim 6 mg subcutaneous day 1 from the first cycle (27 in arm A, 23 in arm B and 29 in arm C). The safety data of these 79 patients were reported here. Results: Our results showed grade 3/4: neutropenia (arm A 30 %, arm B 39 %, arm C 31 %) and febrile neutropenia (FN) (arm A 11 %, arm B 13 %, arm C 3 %), grade 2–4: anaemia (arm A 26 %, arm B 61 %, arm C 55 %) and thrombocytopenia (arm A 15 %, arm B 9 %, arm C 3 %), respectively. Crude proportion and time to toxicity summaries showed that in dose-dense arms, patients allocated to the EC→ T sequence were more exposed to FN than patients allocated to the T→ EC. In the Cox model taking into account all allocated treatment and age, treatment was a predictor of grade 2–4 anaemia, whereas age was significantly correlated to grade 2–4 thrombocytopenia. There was no clear relationship between haematological toxicity and dose intensity across all treatment arms. Except for nausea (17 % versus 3 %) and neurological toxicity (13 % versus 3 %), non-haematological toxicities were similar in arm B and C. Conclusions: These analyzes confirmed that dose-dense regimens EC→ T or T→ EC are feasible with pegfilgrastim primary prophylaxis. The T→ EC sequence seems to be associated with a better haematological tolerance, and should be the preferred dose-dense regimen providing similar efficacy. The trial was supported by Amgen. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- C. Delbaldo
- Hôpital Henri Mondor, Créteil, France; Association Européenne de Recherche en Oncologie (AERO); Clinique St Catherine, Avignon, France; Centre Hospitalier Régional, La Roche sur Yon, France; Policlinique de Blois, La Chaussée St Victor, France; Clinique St Clotilde, La Réunion, France; Clinique Bon Secours, Chartres, France; Le Centre Azuréen de Cancérologie, Mougins, France; Clinique St Marguerite, Hyères, France; Centre Val d'Aurelle, Montpellier, France; IDDI, Louvain-la-Neuve, Belgium
| | - D. Serin
- Hôpital Henri Mondor, Créteil, France; Association Européenne de Recherche en Oncologie (AERO); Clinique St Catherine, Avignon, France; Centre Hospitalier Régional, La Roche sur Yon, France; Policlinique de Blois, La Chaussée St Victor, France; Clinique St Clotilde, La Réunion, France; Clinique Bon Secours, Chartres, France; Le Centre Azuréen de Cancérologie, Mougins, France; Clinique St Marguerite, Hyères, France; Centre Val d'Aurelle, Montpellier, France; IDDI, Louvain-la-Neuve, Belgium
| | - F. Priou
- Hôpital Henri Mondor, Créteil, France; Association Européenne de Recherche en Oncologie (AERO); Clinique St Catherine, Avignon, France; Centre Hospitalier Régional, La Roche sur Yon, France; Policlinique de Blois, La Chaussée St Victor, France; Clinique St Clotilde, La Réunion, France; Clinique Bon Secours, Chartres, France; Le Centre Azuréen de Cancérologie, Mougins, France; Clinique St Marguerite, Hyères, France; Centre Val d'Aurelle, Montpellier, France; IDDI, Louvain-la-Neuve, Belgium
| | - P. Laplaige
- Hôpital Henri Mondor, Créteil, France; Association Européenne de Recherche en Oncologie (AERO); Clinique St Catherine, Avignon, France; Centre Hospitalier Régional, La Roche sur Yon, France; Policlinique de Blois, La Chaussée St Victor, France; Clinique St Clotilde, La Réunion, France; Clinique Bon Secours, Chartres, France; Le Centre Azuréen de Cancérologie, Mougins, France; Clinique St Marguerite, Hyères, France; Centre Val d'Aurelle, Montpellier, France; IDDI, Louvain-la-Neuve, Belgium
| | - S. Greget
- Hôpital Henri Mondor, Créteil, France; Association Européenne de Recherche en Oncologie (AERO); Clinique St Catherine, Avignon, France; Centre Hospitalier Régional, La Roche sur Yon, France; Policlinique de Blois, La Chaussée St Victor, France; Clinique St Clotilde, La Réunion, France; Clinique Bon Secours, Chartres, France; Le Centre Azuréen de Cancérologie, Mougins, France; Clinique St Marguerite, Hyères, France; Centre Val d'Aurelle, Montpellier, France; IDDI, Louvain-la-Neuve, Belgium
| | - E. Angellier
- Hôpital Henri Mondor, Créteil, France; Association Européenne de Recherche en Oncologie (AERO); Clinique St Catherine, Avignon, France; Centre Hospitalier Régional, La Roche sur Yon, France; Policlinique de Blois, La Chaussée St Victor, France; Clinique St Clotilde, La Réunion, France; Clinique Bon Secours, Chartres, France; Le Centre Azuréen de Cancérologie, Mougins, France; Clinique St Marguerite, Hyères, France; Centre Val d'Aurelle, Montpellier, France; IDDI, Louvain-la-Neuve, Belgium
| | - E. Teissier
- Hôpital Henri Mondor, Créteil, France; Association Européenne de Recherche en Oncologie (AERO); Clinique St Catherine, Avignon, France; Centre Hospitalier Régional, La Roche sur Yon, France; Policlinique de Blois, La Chaussée St Victor, France; Clinique St Clotilde, La Réunion, France; Clinique Bon Secours, Chartres, France; Le Centre Azuréen de Cancérologie, Mougins, France; Clinique St Marguerite, Hyères, France; Centre Val d'Aurelle, Montpellier, France; IDDI, Louvain-la-Neuve, Belgium
| | - J. Berdah
- Hôpital Henri Mondor, Créteil, France; Association Européenne de Recherche en Oncologie (AERO); Clinique St Catherine, Avignon, France; Centre Hospitalier Régional, La Roche sur Yon, France; Policlinique de Blois, La Chaussée St Victor, France; Clinique St Clotilde, La Réunion, France; Clinique Bon Secours, Chartres, France; Le Centre Azuréen de Cancérologie, Mougins, France; Clinique St Marguerite, Hyères, France; Centre Val d'Aurelle, Montpellier, France; IDDI, Louvain-la-Neuve, Belgium
| | - M. Fabbro
- Hôpital Henri Mondor, Créteil, France; Association Européenne de Recherche en Oncologie (AERO); Clinique St Catherine, Avignon, France; Centre Hospitalier Régional, La Roche sur Yon, France; Policlinique de Blois, La Chaussée St Victor, France; Clinique St Clotilde, La Réunion, France; Clinique Bon Secours, Chartres, France; Le Centre Azuréen de Cancérologie, Mougins, France; Clinique St Marguerite, Hyères, France; Centre Val d'Aurelle, Montpellier, France; IDDI, Louvain-la-Neuve, Belgium
| | - E. Quinaux
- Hôpital Henri Mondor, Créteil, France; Association Européenne de Recherche en Oncologie (AERO); Clinique St Catherine, Avignon, France; Centre Hospitalier Régional, La Roche sur Yon, France; Policlinique de Blois, La Chaussée St Victor, France; Clinique St Clotilde, La Réunion, France; Clinique Bon Secours, Chartres, France; Le Centre Azuréen de Cancérologie, Mougins, France; Clinique St Marguerite, Hyères, France; Centre Val d'Aurelle, Montpellier, France; IDDI, Louvain-la-Neuve, Belgium
| |
Collapse
|
9
|
Bondiau PY, Venissac N, Otto J, Pourel N, Berdah JF, Castelno O, Teissier E, De Surmont B, Poudenx M. Chimioradiothérapie concomitante avec cisplatine et docétaxel après chimiothérapie d’induction pour les cancers pulmonaires non à petites cellules, étude de phase II. Cancer Radiother 2008. [DOI: 10.1016/j.canrad.2008.08.059] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
10
|
Poudenx M, Bondiau P, Venissac N, Otto J, Pourel N, Castelnau O, Berdah J, De Surmont Salasc B, Teissier E, Mouroux J. Induction with cisplatin (C) and docetaxel (D) plus concurrent three-dimensional (3D) conformal radiotherapy and weekly C and D for locally advanced non-small cell lung cancer (NSCLC) patients (pts): Phase II trial. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.7585] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
11
|
Piedbois P, Serin D, Priou F, Laplaige P, Greget S, Angellier E, Teissier E, Berdah JF, Fabbro M, Valenza B, Herait P, Jehl V, Buyse M. Dose-dense adjuvant chemotherapy in node-positive breast cancer: docetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks. AERO B03 randomized phase II study. Ann Oncol 2007; 18:52-57. [PMID: 17047001 DOI: 10.1093/annonc/mdl355] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND Adding a taxane to anthracycline-based adjuvant chemotherapy prolongs survival in node-positive patients but optimal dose and schedule remain undetermined. This study aimed to select a dose-dense regimen for further assessment in phase III studies. PATIENTS AND METHODS Ninety-nine patients with node-positive invasive breast adenocarcinoma were randomly assigned to docetaxel (Taxotere) (T) 75 mg/m2, epirubicin (E) 75 mg/m2 and cyclophosphamide (C) 500 mg/m2 (TEC)x6, every 3 weeks; E 100 mg/m2, C 600 mg/m2 x 4, then T 100 mg/m2 x 4 (EC-->T) or the reverse sequence (T-->EC), every 2 weeks, with pegfilgrastim support. The primary end point was the incidence of grade 4 toxicity. RESULTS Dose intensity was almost doubled with dose-dense regimens, compared with TEC. Twenty-seven patients experienced grade 4 toxicity: 26%, 40% and 18% with TEC, EC-->T and T-->EC, respectively, mainly neutropenia, but febrile neutropenia occurred only in 11%, 10% and 3%. Grade 3-4 nail disorders, hand-foot syndrome and peripheral neuropathy occurred in 46%, 73% and 68% of patients with TEC, EC-->T and T-->EC, respectively. CONCLUSIONS Dose-dense regimens yield more frequent and severe nonhematological toxic effects than standard dose TEC regimen. Though grade 4 toxicity rates appear acceptable with the T-->EC regimen, the incidence of grade 3-4 events makes it difficult to recommend either dose-dense regimen for further investigation.
Collapse
Affiliation(s)
| | - D Serin
- Institut Sainte-Catherine, Avignon
| | - F Priou
- Hôpital départemental, La Roche-sur-Yon
| | - P Laplaige
- Clinique Saint-Come et Saint-Damien, Blois
| | - S Greget
- Clinique Sainte-Clotilde, Saint-Louis de la Réunion
| | | | | | | | - M Fabbro
- CRLCC Val d'Aurelle, Montpellier
| | - B Valenza
- Centre Hospitalier, Draguignan, France, for the European Association for Research in Oncology
| | | | - V Jehl
- International Drug Development Institute, Brussels, Belgium
| | - M Buyse
- International Drug Development Institute, Brussels, Belgium
| |
Collapse
|
12
|
Martel-Lafay I, Clavère P, Labat J, Benchalal M, Talabard J, Teissier E, d’Hombres A, Touboul E, Vergnenègre A, Fournel P. 1034. Int J Radiat Oncol Biol Phys 2006. [DOI: 10.1016/j.ijrobp.2006.07.299] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
13
|
Piedbois PP, Serin D, Priou F, Laplaige P, Greget S, Angellier E, Teissier E, Berdah JF, Fabbro M, Valenza B. AERO-B03: A randomized phase II trial of dose-dense docetaxel in node-positive breast cancer. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.647] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- P.-P. Piedbois
- Hosp Henri Mondor, APHP, Creteil, France; Inst Sainte Catherine, Avignon, France; Hosp Departemental, La Roche Sur Yon, France; Clin Saint-Come et Saint-Damien, Blois, France; Clin Sainte Clotilde, Saint Denis de la Reunion, France; Hôpital Fontenoy, Chartres, France; Ctr Azureen de Cancerologie, Mougins, France; Clin de l’Espérance, Hyeres, France; CRLC Val d’Aurelle, Montpellier, France; Ctr Hospitalier, Draguignan, France
| | - D. Serin
- Hosp Henri Mondor, APHP, Creteil, France; Inst Sainte Catherine, Avignon, France; Hosp Departemental, La Roche Sur Yon, France; Clin Saint-Come et Saint-Damien, Blois, France; Clin Sainte Clotilde, Saint Denis de la Reunion, France; Hôpital Fontenoy, Chartres, France; Ctr Azureen de Cancerologie, Mougins, France; Clin de l’Espérance, Hyeres, France; CRLC Val d’Aurelle, Montpellier, France; Ctr Hospitalier, Draguignan, France
| | - F. Priou
- Hosp Henri Mondor, APHP, Creteil, France; Inst Sainte Catherine, Avignon, France; Hosp Departemental, La Roche Sur Yon, France; Clin Saint-Come et Saint-Damien, Blois, France; Clin Sainte Clotilde, Saint Denis de la Reunion, France; Hôpital Fontenoy, Chartres, France; Ctr Azureen de Cancerologie, Mougins, France; Clin de l’Espérance, Hyeres, France; CRLC Val d’Aurelle, Montpellier, France; Ctr Hospitalier, Draguignan, France
| | - P. Laplaige
- Hosp Henri Mondor, APHP, Creteil, France; Inst Sainte Catherine, Avignon, France; Hosp Departemental, La Roche Sur Yon, France; Clin Saint-Come et Saint-Damien, Blois, France; Clin Sainte Clotilde, Saint Denis de la Reunion, France; Hôpital Fontenoy, Chartres, France; Ctr Azureen de Cancerologie, Mougins, France; Clin de l’Espérance, Hyeres, France; CRLC Val d’Aurelle, Montpellier, France; Ctr Hospitalier, Draguignan, France
| | - S. Greget
- Hosp Henri Mondor, APHP, Creteil, France; Inst Sainte Catherine, Avignon, France; Hosp Departemental, La Roche Sur Yon, France; Clin Saint-Come et Saint-Damien, Blois, France; Clin Sainte Clotilde, Saint Denis de la Reunion, France; Hôpital Fontenoy, Chartres, France; Ctr Azureen de Cancerologie, Mougins, France; Clin de l’Espérance, Hyeres, France; CRLC Val d’Aurelle, Montpellier, France; Ctr Hospitalier, Draguignan, France
| | - E. Angellier
- Hosp Henri Mondor, APHP, Creteil, France; Inst Sainte Catherine, Avignon, France; Hosp Departemental, La Roche Sur Yon, France; Clin Saint-Come et Saint-Damien, Blois, France; Clin Sainte Clotilde, Saint Denis de la Reunion, France; Hôpital Fontenoy, Chartres, France; Ctr Azureen de Cancerologie, Mougins, France; Clin de l’Espérance, Hyeres, France; CRLC Val d’Aurelle, Montpellier, France; Ctr Hospitalier, Draguignan, France
| | - E. Teissier
- Hosp Henri Mondor, APHP, Creteil, France; Inst Sainte Catherine, Avignon, France; Hosp Departemental, La Roche Sur Yon, France; Clin Saint-Come et Saint-Damien, Blois, France; Clin Sainte Clotilde, Saint Denis de la Reunion, France; Hôpital Fontenoy, Chartres, France; Ctr Azureen de Cancerologie, Mougins, France; Clin de l’Espérance, Hyeres, France; CRLC Val d’Aurelle, Montpellier, France; Ctr Hospitalier, Draguignan, France
| | - J. F. Berdah
- Hosp Henri Mondor, APHP, Creteil, France; Inst Sainte Catherine, Avignon, France; Hosp Departemental, La Roche Sur Yon, France; Clin Saint-Come et Saint-Damien, Blois, France; Clin Sainte Clotilde, Saint Denis de la Reunion, France; Hôpital Fontenoy, Chartres, France; Ctr Azureen de Cancerologie, Mougins, France; Clin de l’Espérance, Hyeres, France; CRLC Val d’Aurelle, Montpellier, France; Ctr Hospitalier, Draguignan, France
| | - M. Fabbro
- Hosp Henri Mondor, APHP, Creteil, France; Inst Sainte Catherine, Avignon, France; Hosp Departemental, La Roche Sur Yon, France; Clin Saint-Come et Saint-Damien, Blois, France; Clin Sainte Clotilde, Saint Denis de la Reunion, France; Hôpital Fontenoy, Chartres, France; Ctr Azureen de Cancerologie, Mougins, France; Clin de l’Espérance, Hyeres, France; CRLC Val d’Aurelle, Montpellier, France; Ctr Hospitalier, Draguignan, France
| | - B. Valenza
- Hosp Henri Mondor, APHP, Creteil, France; Inst Sainte Catherine, Avignon, France; Hosp Departemental, La Roche Sur Yon, France; Clin Saint-Come et Saint-Damien, Blois, France; Clin Sainte Clotilde, Saint Denis de la Reunion, France; Hôpital Fontenoy, Chartres, France; Ctr Azureen de Cancerologie, Mougins, France; Clin de l’Espérance, Hyeres, France; CRLC Val d’Aurelle, Montpellier, France; Ctr Hospitalier, Draguignan, France
| |
Collapse
|
14
|
Martin-Nizard F, Tailleux A, Torpier G, Furman C, Yous S, Teissier E, Fruchart J, Duriez P. W12-P-037 An increased susceptibility of LDL to oxidation in mice treated with a melatonin-related compound is not associated with progression of atherosclerosis. ATHEROSCLEROSIS SUPP 2005. [DOI: 10.1016/s1567-5688(05)80281-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
15
|
Gizard F, Teissier E, Dufort I, Luc G, Luu-The V, Staels B, Hum DW. The transcriptional regulating protein of 132 kDa (TReP-132) differentially influences steroidogenic pathways in human adrenal NCI-H295 cells. J Mol Endocrinol 2004; 32:557-69. [PMID: 15072559 DOI: 10.1677/jme.0.0320557] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
Steroid hormones synthesized from cholesterol in the adrenal gland are important regulators of many physiological processes. It is now well documented that the expression of many genes required for steroid biosynthesis is dependent on the coordinated expression of the nuclear receptor steroidogenic factor-1 (SF-1). However, transcriptional mechanisms underlying the species-specific, developmentally programmed and hormone-dependent modulation of the adrenal steroid pathways remain to be elucidated. Recently, we demonstrated that the transcriptional regulating protein of 132 kDa (TReP-132) acts as a coactivator of SF-1 to regulate human P450scc gene transcription in human adrenal NCI-H295 cells. The present study shows that overexpression of TReP-132 increases the level of active steroids produced in NCI-H295 cells. The conversion of pregnenolone to downstream steroids following TReP-132 expression showed increased levels of glucocorticoids, C(19) steroids and estrogens. Correlating with these data, TReP-132 increases P450c17 activities via the induction of transcript levels and promoter activity of the P450c17 gene, an effect that is enhanced in the presence of cAMP or SF-1. In addition, P450aro activity and mRNA levels are highly induced by TReP-132, whereas 3beta-hydroxysteroid dehydrogenase type II and P450c11aldo transcript levels are only slightly modulated. Taken together, these results demonstrate that TReP-132 is a trans-acting factor of genes involved in adrenal glucocorticoid, C(19) steroid and estrogen production.
Collapse
Affiliation(s)
- F Gizard
- Centre de Recherche en Endocrinologie Moléculaire et Oncologique, Université Laval, Quebec, Canada
| | | | | | | | | | | | | |
Collapse
|
16
|
Quettier-Deleu C, Voiselle G, Fruchart JC, Duriez P, Teissier E, Bailleul F, Vasseur J, Trotin F. Hawthorn extracts inhibit LDL oxidation. Pharmazie 2003; 58:577-81. [PMID: 12967038] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 03/04/2023]
Abstract
Polyphenol-rich diet decreases cardiovascular risk. LDL oxidation is the primary event in atherosclerosis plaque formation and antioxidants such as polyphenols were shown to inhibit LDL oxidation and atherosclerosis development. Hawthorn (Crataegus) and derived pharmaceuticals are rich in polyphenols and already prescribed to treat moderate heart failure, nervousness and sleep disorders. Extracts either from fresh plant parts (flower buds, flowers, young leaves or green fruits) or from dried pharmaceutical parts (flowers and flowering tops) were previously shown to be effective inhibitors of lipoperoxidation and scavengers of oxygen species. In this study, the capacity of total and ethyl-acetate extracts from dried pharmaceutical flowers, tops and fruits to inhibit Cu(2+)-induced LDL oxidation was tested. This capacity was positively linked to their content in total polyphenols, proanthocyanidins (global and oligomeric forms), as well as to their content in two individual phenolics: a flavanol, the dimeric procyanidin B2 and a flavonol glycoside, hyperoside. Flavanol-type phenolics showed to be higher active than the majority of the flavonoids tested in inhibiting Cu(2+)-induced LDL peroxidation. This study suggests that hawthorn could be a source of polyphenols able to inhibit LDL oxidation.
Collapse
Affiliation(s)
- C Quettier-Deleu
- Laboratoire de Pharmacognosie, Faculté de Pharmacie, Institut Pasteur, Lille, France
| | | | | | | | | | | | | | | |
Collapse
|
17
|
Furman C, Lebeau J, Fruchart J, Bernier J, Duriez P, Cotelle N, Teissier E. Di-tert-butylhydroxylated flavonoids protect endothelial cells against oxidized LDL-induced cytotoxicity. J Biochem Mol Toxicol 2002; 15:270-8. [PMID: 11835624 DOI: 10.1002/jbt.10003] [Citation(s) in RCA: 41] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
The protective effect of di-tert-butylhydroxylated flavonoids (chalcones and arylidenes) against minimally oxidized LDL (mO-LDL)-induced cytotoxicity was studied in cultured bovine aortic endothelial cells. Most of the tested compounds decreased aldehydes formation in medium containing mO-LDL, but their capacity to inhibit LDL oxidation in the cellular medium was not sufficient to totally reduce the cellular toxicity of mO-LDL. Most of the tested flavonoids improved the integrity of cells exposed to mO-LDL, whereas butylated hydroxytoluene was ineffective and quercetin worsened the toxicity of mO-LDL. Moreover these flavonoids induced an increase in GSH cellular levels and their protective effects might be because of their inability to reduce metal ion. Arylidene 6 substituted at position 7 by a hydroxyl group was the most potent compound.
Collapse
Affiliation(s)
- C Furman
- Département de Recherches sur les Lipoprotéines et l'Athérosclérose, INSERM U325, Institut Pasteur et Faculté de Pharmacie, Université de Lille 2, 59000 Lille, France
| | | | | | | | | | | | | |
Collapse
|
18
|
Gbaguidi FG, Chinetti G, Milosavljevic D, Teissier E, Chapman J, Olivecrona G, Fruchart JC, Griglio S, Fruchart-Najib J, Staels B. Peroxisome proliferator-activated receptor (PPAR) agonists decrease lipoprotein lipase secretion and glycated LDL uptake by human macrophages. FEBS Lett 2002; 512:85-90. [PMID: 11852057 DOI: 10.1016/s0014-5793(02)02223-8] [Citation(s) in RCA: 59] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
Lipoprotein lipase (LPL) acts independently of its function as triglyceride hydrolase by stimulating macrophage binding and uptake of native, oxidized and glycated LDL. Peroxisome proliferator-activated receptors (PPARs) are nuclear receptors expressed in monocyte/macrophages, where they control cholesterol homeostasis. Here we study the role of PPARs in the regulation of LPL expression and activity in human monocytes and macrophages. Incubation of human monocytes or macrophages with PPARalpha or PPARgamma ligands increases LPL mRNA and intracellular protein levels. By contrast, PPAR activators decrease secreted LPL mass and enzyme activity in differentiated macrophages. These actions of PPAR activators are associated with a reduced uptake of glycated LDL and could influence atherosclerosis development associated with diabetes.
Collapse
Affiliation(s)
- F G Gbaguidi
- UR. 545 INSERM and Université de Lille 2, Lille, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Cutuli B, Borel C, Dhermain F, Magrini SM, Wasserman TH, Bogart JA, Provencio M, de Lafontan B, de la Rochefordiere A, Cellai E, Graic Y, Kerbrat P, Alzieu C, Teissier E, Dilhuydy JM, Mignotte H, Velten M. Breast cancer occurred after treatment for Hodgkin's disease: analysis of 133 cases. Radiother Oncol 2001; 59:247-55. [PMID: 11369065 DOI: 10.1016/s0167-8140(01)00337-1] [Citation(s) in RCA: 76] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
PURPOSE To assess the clinical and histological characteristics of breast cancer (BC) occurring after Hodgkin's disease (HD) and give possible therapies and prevention methods. MATERIALS AND METHODS In a retrospective multicentric analysis, 117 women and two men treated for HD subsequently developed 133 BCs. The median age at diagnosis of HD was 24 years. The HD stages were stage I in 25 cases (21%), stage II in 70 cases (59%), stage III in 13 cases (11%), stage IV in six cases (5%) and not specified in five cases (4%). Radiotherapy (RT) was used alone in 74 patients (63%) and combined modalities with chemotherapy (CT) was used in 43 patients (37%). RESULTS BC occurred after a median interval of 16 years. TNM classification (UICC, 1978) showed 15 T0 (11.3%), 44 T1 (33.1%), 36 T2 (27.1%), nine T3 (6.7%), 15 T4 (11.3%) and 14 Tx (10.5%). Ductal infiltrating carcinoma and ductal carcinoma in situ (DCIS) represented 81.2 and 11.3% of the cases, respectively. Among the infiltrating carcinoma, the axillary involvement rate was 50%. Seventy-four tumours were treated by mastectomy without (67) or with (ten) RT. Forty-four tumours had lumpectomy without (12) or with (32) RT. Another four received RT alone, and one CT alone. Sixteen patients (12%) developed isolated local recurrence. Thirty-nine patients (31.7%) developed metastases and 34 died; 38 are in complete remission whereas five died of intercurrent disease. The 5-year disease-specific survival rate was 65.1%. The 5-year disease-specific survival rates for the pN0, pN1-3 and pN>3 groups were 91, 66 and 15%, respectively (P<0.0001), and 100, 88, and 64% for the TIS, T1 and T2. For the T3 and T4, the survival rates decreased sharply to 32 and 23%, respectively. These secondary BC are of two types: a large number of aggressive tumours with a very unfavourable prognosis (especially in the case of pN>3 and/or T3T4), and many tumours with a 'slow spreading' such as DCIS and microinvasive lesions. These lesions developed especially in patients treated exclusively by RT. CONCLUSIONS The young women and girls treated for HD should be carefully monitored in the long-term by clinical examination, mammography and ultrasonography. We suggest that a baseline mammography is performed 5-8 years after supradiaphragmatic irradiation (complete mantle or involved field) in patients who were treated before 30 years of age. Subsequent mammographies should be performed every 2 years or each year, depending on the characteristics of the breast tissue (e.g. density) and especially in the case of an association with other BC risk factors. This screening seems of importance due to excellent prognosis in our T(1S)T(1) groups, and the possibility of offering these young women a conservative treatment.
Collapse
Affiliation(s)
- B Cutuli
- Department of Radiotherapy, Centre Paul Strauss, 3 Rue de la Porte de l'Hôpital, 67085 Cedex, Strasbourg, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Chinetti G, Lestavel S, Bocher V, Remaley AT, Neve B, Torra IP, Teissier E, Minnich A, Jaye M, Duverger N, Brewer HB, Fruchart JC, Clavey V, Staels B. PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med 2001; 7:53-8. [PMID: 11135616 DOI: 10.1038/83348] [Citation(s) in RCA: 856] [Impact Index Per Article: 37.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
Peroxisome proliferator-activated receptors (PPARs) are nuclear receptors that regulate lipid and glucose metabolism and cellular differentiation. PPAR-alpha and PPAR-gamma are both expressed in human macrophages where they exert anti-inflammatory effects. The activation of PPAR-alpha may promote foam-cell formation by inducing expression of the macrophage scavenger receptor CD36. This prompted us to investigate the influence of different PPAR-activators on cholesterol metabolism and foam-cell formation of human primary and THP-1 macrophages. Here we show that PPAR-alpha and PPAR-gamma activators do not influence acetylated low density lipoprotein-induced foam-cell formation of human macrophages. In contrast, PPAR-alpha and PPAR-gamma activators induce the expression of the gene encoding ABCA1, a transporter that controls apoAI-mediated cholesterol efflux from macrophages. These effects are likely due to enhanced expression of liver-x-receptor alpha, an oxysterol-activated nuclear receptor which induces ABCA1-promoter transcription. Moreover, PPAR-alpha and PPAR-gamma activators increase apoAI-induced cholesterol efflux from normal macrophages. In contrast, PPAR-alpha or PPAR-gamma activation does not influence cholesterol efflux from macrophages isolated from patients with Tangier disease, which is due to a genetic defect in ABCA1. Here we identify a regulatory role for PPAR-alpha and PPAR-gamma in the first steps of the reverse-cholesterol-transport pathway through the activation of ABCA1-mediated cholesterol efflux in human macrophages.
Collapse
Affiliation(s)
- G Chinetti
- Institut Pasteur and U325 INSERM and Université de Lille 2, Lille, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Abstract
Epidemiological evidence suggests an inverse relationship between dietary intake of flavonoids and cardiovascular risk. The biological activities of flavonoids are related to their antioxidative effects, but they also can be mutagenic, due to the prooxidant activity of the catechol pattern. To prevent these problems, we synthesized new flavonoids where one or two di-tert-butylhydroxyphenyl (DBHP) groups replaced catechol moiety at position 2 of the benzopyrane heterocycle. Two DBHP moieties can also be arranged in an arylidene structure or one DBHP fixed on a chalcone structure. Position 7 on the flavone and arylidene or position 4 on the chalcone was substituted by H, OCH(3), or OH. New structures were compared with quercetin and BHT in an LDL oxidation system induced by Cu(II) ions. Arylidenes and chalcones had the best activities (ED(50) = 0.86 and 0.21) compared with vitamin E, BHT, and quercetin (ED(50) = 10.0, 7. 4, and 2.3 microM). Activity towards stable free radical 1, 1-diphenyl-2-picryl-hydrazyl (DPPH) was measured by log Z and ECR(50) parameters. Synthesized flavones proved to be poor DPPH radical scavengers, the activity increasing with the number of DBHP units. In contrast, arylidenes and chalcones were stronger DPPH radical scavengers (log Z > 3, 0.3 < ECR(50) < 2.12) than BHT (log Z = 0.75, ECR(50) = 12.56) or quercetin (log Z = 2.76, ECR(50) = 0.43). Unlike quercetin, synthesized compounds neither chelated nor reduced copper, proving that these new flavonoids had no prooxidant activity in vitro.
Collapse
Affiliation(s)
- J Lebeau
- Laboratoire de Chimie Organique et Macromoléculaire, UPRESA 8009, 59655, Villeneuve d'Ascq, France
| | | | | | | | | | | |
Collapse
|
22
|
Abstract
In vivo low density protein (LDL) oxidation is a progressive phenomenon leading to the presence of minimally and highly oxidized LDLs in the subendothelial arterial space. Oxidized LDLs have been reported to be cytotoxic against endothelial cells. The goal of this study was to determine which of the minimally and highly oxidized LDLs were the most cytotoxic against bovine aortic endothelial cells (BAEC). Both the morphological aspect of the cells themselves, and LDH or MTT tests revealed that mO- or Cu-LDLs had similar cytotoxicity with up to 8 hours of oxidation, showing no relation with the level of LDL oxidation; for longer oxidation times, Cu-LDL cytotoxicity decreased. This phenomenon is linked to their different oxidation kinetics. Moreover, in the initial hours following BAEC incubation with mO- or Cu-LDLs, total cell glutathione dropped, whereas after 16 hours of incubation, highly oxidized Cu-LDL increased the glutathione level in the cell. The biphasic evolution of glutathione concentration corresponds to an autoprotective mechanism of cells against oxidized LDL cytotoxicity. This study suggests that the specific chemical characteristics of the different types of oxidized LDLs should always be precisely described in future assays devoted to studying the biological effects of what are known under the generic term as "oxidized LDLs". This precaution should prevent any confusion in interpreting different studies.
Collapse
Affiliation(s)
- C Furman
- Département d'Athérosclérose and INSERM U 325, Pasteur Institute, Lille, France
| | | | | | | | | |
Collapse
|
23
|
Lambert M, Boullier A, Hachulla E, Fruchart JC, Teissier E, Hatron PY, Duriez P. Paraoxonase activity is dramatically decreased in patients positive for anticardiolipin antibodies. Lupus 2000; 9:299-300. [PMID: 10866101 DOI: 10.1191/096120300680198980] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
It has been reported that paraoxonase 1 (PON1) activity inhibits low-density lipoprotein (LDL) oxidation and modulates the risk of coronary heart disease. This study shows that autoantibodies (IgG) directed against modified LDL were increased in 71 patients positive for anticardiolipin antibodies. In a representative subgroup of these patients (n = 36) PON1 activity was dramatically decreased and the prevalence of the RR genotype of this enzyme tended to be increased in patients who had developed arterial thrombosis. This study suggests that PON1 abnormalities play a role in the antiphospholipid syndrome.
Collapse
Affiliation(s)
- M Lambert
- Department of Internal Medicine, Huriez Hospital, University Hospital, University of Lille 2, France
| | | | | | | | | | | | | |
Collapse
|
24
|
Zoete V, Bailly F, Vezin H, Teissier E, Duriez P, Fruchart JC, Catteau JP, Bernier JL. 4-Mercaptoimidazoles derived from the naturally occurring antioxidant ovothiols 1. Antioxidant properties. Free Radic Res 2000; 32:515-24. [PMID: 10798717 DOI: 10.1080/10715760000300521] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Abstract
4-Mercaptoimidazoles derived from the naturally occurring family of antioxidants, the ovothiols, were assayed for their antioxidant properties. These compounds are powerful HOCl scavengers, more potent than the aliphatic thiol N-acetylcysteine. They react slowly with hydrogen peroxide with second order rate constants of 0.13-0.89 M(-1)s(-1). Scavenging of hydroxyl radical occurs at a diffusion-controlled rate (k=2.0-5.0 x 10(10)M(-1)s(-1)) for the most active compounds, which are also able to inhibit copper-induced LDL peroxidation. The combination of radical scavenging and copper chelating properties may explain the inhibitory effects on LDL peroxidation. Two molecules of mercaptoimidazole can chelate a copper ion and form a square planar complex detected by EPR. Compounds bearing an electron-withdrawing group on position 2 of the imidazole ring are the most potent antioxidant molecules in this series.
Collapse
Affiliation(s)
- V Zoete
- Laboratoire de Chimie Organique Physique associée à l'Ecole Nationale Supérieure de Chimie de Lille, ESA CNRS 8009, Villeneuve d'Ascq, France
| | | | | | | | | | | | | | | |
Collapse
|
25
|
Abstract
The peroxisome proliferator-activated receptor alpha (PPARalpha) is a transcription factor belonging to the PPAR subfamily of nuclear receptors. Fatty acids and eicosanoids are natural PPARalpha ligands. Here, we show using transient transfection assays that oxidized (oxLDL) but not native low-density lipoproteins (LDL) dose-dependently activate PPARalpha in endothelial cells without affecting PPARalpha protein expression. Fractioning of oxLDL lipids followed by transactivation experiments demonstrated that the oxidized phospholipid component in oxLDL is responsible for PPARalpha activation. Using specific inhibitors, it is shown that oxLDL-mediated PPARalpha activation requires phospholipase A2 activity and that the oxidized fatty acids 9- and 13-HODE activate PPARalpha directly. Finally, we found that, similar to the synthetic PPARalpha ligand Wy-14643, oxLDL induced expression of the fatty acid transport protein-1 in human primary endothelial cells. Our findings define a novel group of PPARalpha activators and provide a molecular basis for certain effects of these biologically active phospholipids on gene transcription.
Collapse
Affiliation(s)
- P Delerive
- INSERM U.325, Département d'Athérosclérose, Institut Pasteur de Lille, 1 Rue Calmette, P.O. Box 245, 59019, Lille, France
| | | | | | | | | | | |
Collapse
|
26
|
Abstract
From the European plant Ballota nigra L. various polyphenols including phenylpropanoid derivatives were isolated. There is increasing evidence that oxidized low-density lipoproteins (Ox-LDL) might be involved in the pathogenesis of atherosclerosis and it has been reported that polyphenols inhibit LDL peroxidation and atherogenesis. The goal of this study was to test whether the major polyphenolic compounds extracted from Ballota nigra, four phenylpropanoid glycosides, verbascoside, forsythoside B, arenarioside, and ballotetroside and one non-glycosidic phenylpropanoid, caffeoyl-L-malic acid, inhibit Cu(2+)-induced LDL peroxidation. The effectiveness of these compounds was compared to the activity of quercetin, a well-known polyphenol inhibitor of Cu(2+)-induced LDL oxidation. Antioxidant efficacious doses (ED 50) of arenarioside and ballotetroside were 1.8 microM and 7.5 microM respectively, while in the same conditions, the ED 50 of forsythoside B and verbascoside were similar (1 microM) and those of quercetin and of caffeoyl-L-malic acid were 2.3 microM and 9.5 microM respectively. Spectrophotometric studies show that quercetin is a Cu(2+) chelator while phenylpropanoid glycosides and caffeoyl-L-malic acid are not Cu(2+) chelators. Therefore, phenylpropanoid glycosides are strong inhibitors of Cu(2+)-induced LDL oxidation, independent of any capacity to act as Cu(2+) chelators.
Collapse
Affiliation(s)
- V Seidel
- Laboratoire de Pharmacognosie, Faculté de Pharmacie, Université de Lille 2, 3 rue du Professeur Laguesse, BP 83, 59006 Lille, France
| | | | | | | | | | | | | | | |
Collapse
|
27
|
Ferrero JM, Etienne MC, Formento JL, Francoual M, Rostagno P, Peyrottes I, Ettore F, Teissier E, Leblanc-Talent P, Namer M, Milano G. Application of an original RT-PCR-ELISA multiplex assay for MDR1 and MRP, along with p53 determination in node-positive breast cancer patients. Br J Cancer 2000; 82:171-7. [PMID: 10638986 PMCID: PMC2363171 DOI: 10.1054/bjoc.1999.0896] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
The long-term prognostic value of tumoural MDR1 and MRP, along with p53 and other classical parameters, was analysed on 85 node-positive breast cancer patients receiving anthracycline-based adjuvant therapy. All patients underwent tumour resection plus irradiation and adjuvant chemotherapy (the majority receiving fluorouracil-epirubicin-cyclophosphamide). Median follow-up for the 54 alive patients was 7.8 years. Mean age was 53.7 years (range 28-79) and 54 patients were post-menopausal. MDR1 and MRP expression were quantified according to an original reverse transcription polymerase chain reaction multiplex assay with colourimetric enzyme-linked immunosorbent assay detection (beta2-microglobulin as control). P53 protein was analysed using an immunoluminometric assay (Sangtec). MDR1 expression varied within an 11-fold range (mean 94, median 83), MRP within a 45-fold range (mean 315, median 242) and p53 protein from the limit of detection (0.002 ng mg(-1)) up to 35.71 ng mg(-1) (mean 1.18, median 0.13 ng mg(-1)). P53 protein was significantly higher in oestrogen receptor (ER)-negative than in ER-positive tumours (P = 0.039). The higher the p53, the lower the MDR1 expression (P = 0.015, r= -0.27). P53 was not linked to progesterone receptor (PR) status, S phase fraction, or MRP Significantly greater MDR1 expression was observed in grade I tumours (P = 0.029). No relationship was observed between MDR1 and MRP. Neither MDR1 nor MRP was linked to ER or PR status. Unlike MDR1, MRP was correlated with the S phase: the greater the MRP, the lower the S phase (P = 0.006, r = -0.42). Univariate Cox analyses revealed that MDR1, MRP, p53 and S phase had no significant influence on progression-free or specific survival. A tendency suggested that the greater the p53, the shorter the progression-free survival (P = 0.076 as continuous and 0.069 as dichotomous).
Collapse
Affiliation(s)
- J M Ferrero
- Centre Antoine Lacassagne, Oncopharmacology Unit, Nice, France
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Trottein F, Nutten S, Angeli V, Delerive P, Teissier E, Capron A, Staels B, Capron M. Schistosoma mansoni schistosomula reduce E-selectin and VCAM-1 expression in TNF-alpha-stimulated lung microvascular endothelial cells by interfering with the NF-kappaB pathway. Eur J Immunol 1999; 29:3691-701. [PMID: 10556825 DOI: 10.1002/(sici)1521-4141(199911)29:11<3691::aid-immu3691>3.0.co;2-l] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
The recruitment of immune cells into the lungs is a key step in protection against murine schistosomiasis. In this phenomenon, pulmonary (micro)vascular endothelial cells (EC) probably play a central role, by expressing specific adhesion molecules on their surface. Recently, we have shown that Schistosoma mansoni schistosomula, the parasitic stage which resides in the lungs, could activate microvascular EC to acquire an anti-inflammatory phenotype. In the present study, we tested the hypothesis that schistosomula could also regulate the expression of adhesion molecules in vitro by human lung microvascular EC (HMVEC-l) in the present of the pro-inflammatory cytokine TNF-alpha. We found that lipophilic substance(s) present in the excretory/secretory products from schistosomula selectively reduce the TNF-alpha-induced synthesis of E-selectin and VCAM-1 mRNA and proteins without affecting ICAM-1. This inhibitory effect appears to be mediated by a cyclic AMP/protein kinase A (cAMP/PKA) pathway that probably interferes with the NF-kappaB pathway induced by TNF-alpha at the level of the E-selectin promoter, whereas a cAMP-independent pathway appears to operate in VCAM-1 down-modulation. Finally, schistosomula also significantly reduce the VLA-4/VCAM-1-dependent adherence of leukocytes to TNF-alpha-stimulated HMVEC-l. We speculate that this mechanism could represent a new stratagem that parasites may use to escape the immune system by controlling leukocyte recruitment to the lungs.
Collapse
Affiliation(s)
- F Trottein
- Centre d'Immunologie et de Biologie, Parasitaire INSERM U167, Institut Pasteur de Lille, Lille, France.
| | | | | | | | | | | | | | | |
Collapse
|
29
|
Cutuli B, Borel C, Dhermain F, Magrini S, Wassermann T, Bogart J, Provencio M, de Lafontan B, de Larochefordiere A, Graic Y, Kerbrat P, Alzieu C, Teissier E, Dilhuydy J, Mignotte H, Velten M. Breast cancer (BC) after cured Hodgkin's disease (HD). Eur J Cancer 1999. [DOI: 10.1016/s0959-8049(99)81750-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
30
|
|
31
|
Vaiva G, Teissier E, Cottencin O, Thomas P, Goudemand M. On suicide and attempted suicide during pregnancy. Crisis 1999; 20:22, 27, 40 passim. [PMID: 10365502 DOI: 10.1027/0227-5910.20.1.22] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
|
32
|
Gozzo A, Lesieur D, Duriez P, Fruchart JC, Teissier E. Structure-activity relationships in a series of melatonin analogues with the low-density lipoprotein oxidation model. Free Radic Biol Med 1999; 26:1538-43. [PMID: 10401620 DOI: 10.1016/s0891-5849(99)00020-9] [Citation(s) in RCA: 44] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
Despite an increasing number of publications concerning the antioxidant activity of melatonin, little is known about the structural features responsible for this kind of activity. To understand the role played by the different elements of melatonin structure in its antioxidant activity, we have designed and tested several compounds related to this molecule in the low-density lipoprotein peroxidation model. We present here the results of this study in terms of structure-activity relationships focusing on the influence of the acetamidoethyl side chain, the methoxy group, and the indole heterocycle. In this model, we found that changing the acyl residue generally resulted in more active products. We obtained particularly good results with the nonanoyl derivative which showed a level of activity comparable to that of phenols despite lacking a phenolic function. The presence of a methoxy group in position 5 generally had a beneficial influence on the activity, but when located in position 6, the effects were various. The substitution of a hydroxy for the methoxy group led to phenolic compounds endowed with very high antioxidant activity. Replacing the amide with a ketone function did not affect the activity while replacement with an amine group in some cases resulted in prooxidant compounds. Finally, we compared the efficacy of different aromatic rings. The indole heterocycle proved to be better than benzofurane and naphthalene rings.
Collapse
Affiliation(s)
- A Gozzo
- Institut de Chimie Pharmaceutique, Université de Lille 2, France.
| | | | | | | | | |
Collapse
|
33
|
Walters-Laporte E, Furman C, Fouquet S, Martin-Nizard F, Lestavel S, Gozzo A, Lesieur D, Fruchart JC, Duriez P, Teissier E. A high concentration of melatonin inhibits in vitro LDL peroxidation but not oxidized LDL toxicity toward cultured endothelial cells. J Cardiovasc Pharmacol 1998; 32:582-92. [PMID: 9781926 DOI: 10.1097/00005344-199810000-00010] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
The pineal hormone, melatonin, was recently found to be a potent free scavenger for hydroxyl and peroxyl radicals. Melatonin also inhibits neuronal and thymocyte damage due to oxidative stress. Atherosclerosis development is mediated by low-density lipoprotein (LDL) oxidation and the endocytosis of oxidized LDL by resident macrophages in the subendothelial vascular wall. Furthermore, the cytotoxic effect of oxidized LDL increases atherogenicity. The goal of this study was to compare the antioxidant activities of melatonin and vitamin E against in vitro LDL oxidation and their cytoprotective actions against oxidized LDL-induced endothelial cell toxicity. An attempt at loading LDL with melatonin by incubating human plasma with an ethanolic melatonin solution gave only low protection against Cu2+-induced LDL oxidation in comparison with vitamin E and gave no detectable incorporation of melatonin into LDL, measured by high-performance liquid chromatography (HPLC) coupled to UV detection. High concentrations of melatonin (10-100 microM) added to the oxidative medium induced a clear inhibition of Cu2+-induced LDL oxidation, characterized as an increase in the lag-phase duration of conjugated diene formation and decreases in the maximal rate of the propagation phase and in the maximal amount of conjugated diene formation. Determination of the median efficacious dose (ED50) of melatonin and vitamin E by their ability to increase lag-phase duration showed that melatonin was less active than vitamin E (ED50, 79 vs. 10 microM, respectively). Melatonin was also less active than vitamin E in limiting the formation of thiobarbituric acid-reactive substances (TBARS) and LDL fluorescence intensity increase in the medium during Cu2+-induced LDL oxidation. Cu2+-induced LDL oxidation in the presence of 100 microM melatonin produced oxidized LDLs that were less recognizable for the scavenger receptors of J774 macrophages than were untreated LDLs. Vitamin E, 10 microM, was more active than 100 microM melatonin in inhibiting LDL oxidation and the resulting lipoprotein alterations leading to binding internalization and degradation by the J774 macrophages. Vitamin E, 100 microM, inhibited the pursuit of the oxidation of oxidized LDL mediated by bovine aortic endothelial cells (BAECs) in a culture medium containing Cu2+, whereas 100 microM melatonin had no antioxidant effect. Melatonin, 100 microM, as well as 100 microM vitamin E inhibited intracellular TBARS formation during the incubation of BAECs with highly oxidized LDL but had no influence on the increase in glutathione (GSH) concentration during this lengthy exposure (16 h) of BAECs to highly oxidized LDL. During this period, the same dose of vitamin E but not of melatonin tended to limit the decrease in adenosine triphosphate (ATP) concentration. Vitamin E, 100 microM, did not significantly reduce cellular lactate dehydrogenase (LDH) release in the culture medium during the incubation of oxidized LDL with BAECs, whereas 100 microM melatonin dramatically increased this release. These data show that melatonin is less active than vitamin E in inhibiting in vitro LDL oxidation and does not inhibit the cytotoxicity of oxidized LDL toward cultured endothelial cells. The concentrations necessary to inhibit LDL oxidation are far beyond those found in human plasma (100 microM vs. 100 pM). Therefore our results indicate that the pineal hormone melatonin per se appears to have little antiatherogenic property in the in vitro oxidation of LDL and the cytoprotective action against the toxicity of oxidized LDL. Nevertheless, in vivo LDL oxidation takes place in the subendothelium of the artery wall, and nothing is known about the concentration of melatonin or its catabolites in this environment.
Collapse
Affiliation(s)
- E Walters-Laporte
- Département d'Athérosclérose, INSERM U325, Institut Pasteur et Faculté de Pharmacie, Lille, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Héry M, Teissier E, Ramaioli A, the Investigators of F.N.C.L.C.C.. Nine years results of breast carcinoma conservative treatment for 295pTI≤ 10mm N— without adjuvant medical treatment. Eur J Cancer 1998. [DOI: 10.1016/s0959-8049(98)80247-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
35
|
Héry M, Teissier E, Ramaioli A, Loeb A, Mihura J, Veiten M, De Ghislain C, Weber B, Servent-Hanon V, Delozier T. L'âge inférieur ou égal à 40 ans est-il une contre-indication traitement conservateur ? Étude de 141 cas sans atteinte axiüaire (N−). Cancer Radiother 1998. [DOI: 10.1016/s1278-3218(98)80040-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
36
|
Bensadoun RJ, Etienne MC, Dassonville O, Chauvel P, Pivot X, Marcy PY, Prevost B, Coche-Dequeant B, Bourdin S, Vallicioni J, Poissonnet G, Courdi A, Teissier E, Lagrange JL, Thyss A, Santini J, Demard F, Schneider M, Milano G. Concomitant b.i.d. radiotherapy and chemotherapy with cisplatin and 5-fluorouracil in unresectable squamous-cell carcinoma of the pharynx: clinical and pharmacological data of a French multicenter phase II study. Int J Radiat Oncol Biol Phys 1998; 42:237-45. [PMID: 9788400 DOI: 10.1016/s0360-3016(98)00235-1] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/09/2023]
Abstract
PURPOSE The aim of this phase II study conducted on unresectable squamous cell carcinoma (USCC) of the oro- and hypopharynx was to associate twice-a-day (b.i.d.) continuous nonaccelerated radiotherapy with concomitant cisplatin (CP)-5-fluorouracil (5-FU) chemotherapy, both given at full dose. Feasibility, efficacy, survival, and pharmacokinetic-pharmacodynamic relationships were analyzed. METHODS AND MATERIALS Fifty-four consecutive patients with strictly USCC of oro- and/or hypopharynx received continuous b.i.d. radiotherapy (RT) (2 daily fractions of 1.2 Gy, 5 days a week, with a 6-h minimal interval between fractions). Total RT dose was 80.4 Gy on the oropharynx and 75.6 Gy on the hypopharynx. Three chemotherapy (CT) courses of CP-5-FU were given during RT at 21-day intervals (third not delivered after the end of RT). CP dose was 100 mg/m2 (day 1) and 5-FU was given as 5-day continuous infusion (day 2-day 6: 750 mg/m2/day cycle 1, 750 mg total dose/day cycle 2 and 3). Pharmacokinetics was performed for 5-FU (105 h follow-up) and CP (single sample at 16 h). Special attention was paid to supportive care. RESULTS Good feasibility of RT was observed (85.2% of patients with total dose > 75 Gy). Five patients received 1 CT cycle, 34: 2 cycles, and 15: 3 cycles. The most frequent and severe acute toxicities were mucositis with grade 3-4 occurring in 28% at cycle 1 and 86% at cycle 2, as well as neutropenia (43% at cycle 2). Locoregional control at 6 months was observed in 66.7% of patients. No late toxicity above grade 2 RTOG was noticed. CP dose and 5-FU AUC(0-105h) were significantly linked to grade 3-4 neutropenia (cycle 2). Cumulative total platinum (Pt) concentration and Karnofsky index were the only independent predictors of locoregional control at 6 months. Finally, total RT dose and total Pt concentration were the only independent predictors of specific survival. CONCLUSION This protocol showed good locoregional response with an acceptable toxicity profile. Pharmacokinetic survey is probably an effective approach to further reduce toxicity and improve efficacy. A multicentric randomized phase III study, now underway, should confirm these encouraging results.
Collapse
Affiliation(s)
- R J Bensadoun
- Department of Radiation Oncology, Centre Antoine-Lacassagne, Nice, France.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Teissier E, Fennrich S, Strazielle N, Daval JL, Ray D, Schlosshauer B, Ghersi-Egea JF. Drug metabolism in in vitro organotypic and cellular models of mammalian central nervous system: activities of membrane-bound epoxide hydrolase and NADPH-cytochrome P-450 (c) reductase. Neurotoxicology 1998; 19:347-55. [PMID: 9621341] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
The membrane-bound form of epoxide hydrolase and NADPH-cytochrome P-450 (c) reductase are two important enzymes involved in the bioactivation/bioinactivation balance of cerebral tissue. In vivo, the developmental profiles and regional localizations of these two enzymes were investigated in the rat. The regional distribution study showed that they are ubiquitously present among the major brain structures. Both enzyme activities were present in the brain prior to birth, and hence tissue from early developmental stages is suitable to develop in vitro cellular or organotypic models for toxicity studies involving these metabolic pathways. Because various neurotoxicological effects can be dependent on spatio-temporally regulated cell-cell interactions, we aimed to employ organotypic tissue cultures in which the cytoarchitecture was well preserved. In such cultures, the temporal expression profiles of epoxide hydrolase and NADPH cytochrome(c) P-450 reductase reflected the in vivo situation. The technically less demanding pure neuronal and glial cell cultures were also investigated. Detoxification of benzopyrene-4,5-epoxide and superoxide production arising from the reductive metabolism of various drugs were determined in all three systems. The results indicate that though organotypic culture is a good model for the metabolic pathways studied, less complicated single cell cultures can also represent appropriate model systems, providing that the expression of the enzymes involved has been first established in these systems. NADPH-cytochrome P-450 reductase-dependent metabolism is active in both neuronal and glial cells, whereas the detoxification of reactive epoxides occurs mainly in glia.
Collapse
Affiliation(s)
- E Teissier
- INSERM U 325, Institut Pasteur de Lille, France
| | | | | | | | | | | | | |
Collapse
|
38
|
Cutuli B, Velten M, Dilhuydy J, De Lafontan B, Lacroze M, Lesaunier F, Graic Y, Marchal C, Spielmann M, Resbeut M, Berlie J, Reme-Saumon M, Gamelin F, Lesimple T, Teissier E, Moncho-Bernier V, Cuillere J, Nguyen T, Campana F, De Gislain C, Tortochaux J. Male breast cancer: Results of the treatments and prognostic factors in 690 cases. Int J Radiat Oncol Biol Phys 1998. [DOI: 10.1016/s0360-3016(98)80363-5] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
39
|
Furman C, Martin F, Fruchart J, Duriez P, Teissier E. 3.P.112 Differential effects of air (mO-LDL) or copper oxidized LDLs (Cu-LDL) on endothelial cell GSH content. Atherosclerosis 1997. [DOI: 10.1016/s0021-9150(97)89188-5] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/16/2022]
|
40
|
Ferrero JM, Largillier R, Ramaioli A, Heudier P, Teissier E, Namer M. [Prognostic value of early normalization of CA 125 during chemotherapy in stages III and IV ovarian tumors]. Bull Cancer 1997; 84:722-8. [PMID: 9339198] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
The value of early CA 125 assays and analysis of its diminution kinetics during chemotherapy have been the subject of numerous studies. In contrast, routine utilization of CA 125 assays in clinical practice remains controversial or at best difficult to apply because the definitions and prognostic values associated with CA 125 assays vary greatly from one study to the next. This study was designed to determine whether serial CA 125 assays during induction chemotherapy for ovarian carcinoma, using simple evaluation criteria directly applicable in routine clinical practice such as early normalization (level < 35 UI/ml) are predictive of response to treatment or improved survival. This retrospective longitudinal analysis concerned a historical population of 140 patients with ovarian carcinoma stages III and IV treated at the Antoine-Lacassagne Cancer Center between 1978 and 1993. All the patients were treated by chemotherapy based on platinum salts every 21 days. Serum CA 125 assays were performed both before and after surgery and during each chemotherapy cycle. Eighty-four patients had a pre-operative CA 125 assay. No difference is observed in survival as a function of their preoperative CA 125 concentration (p = 0.4). Sixty-seven patients had a CA 125 assay the 6th week after initiation of chemotherapy, 62 the 9th week and 47 the 18th week. Normalization of CA 125 the 6th week (p = 0.0001), the 9th week (p = 0.0008) and the 18th week (p = 0.03) after the initiation of the chemotherapy cycle are correlated with survival. The median survival in our study is 42 months if the CA 125 is below 35 UI/ml the 6th week versus 13 months if the level of CA 125 remains more than 35 UI/ml. In all, 66 of the 105 FIGO stage III patients underwent second-look surgery. Normalization of CA 125 levels is correlated with the absence of any gross residual tumor at the second-look procedure, the 6th week of chemotherapy (p = 0.0019), the 9th week of chemotherapy (p = 0.0003) and the 18th week of chemotherapy (p = 0.0015). This correlation is not confirmed when the presence of histologic residual tumor in biopsy specimens obtained during second-look surgery is taken into consideration. Overall, 88% of patients whose CA 125 levels failed to normalize during evaluation at the second cycle of chemotherapy have residual tumor at second-look surgery. Outside of clinical trials, repeated early CA 125 assays to determine the chemosensitivity and the prognosis of patients with ovarian carcinoma are of little interest compared to a single CA 125 assay at the 6th week after initiation of chemotherapy. This approach seems to be a good compromise between the information sought and its practical use. However the interest of early modification of chemotherapy regimen after 2 cycles, if the level of CA 125 remains more than 35 UI/ml, will have to be showed.
Collapse
Affiliation(s)
- J M Ferrero
- Département d'oncologie médicale, Centre Antoine-Lacassagne, Nice, France
| | | | | | | | | | | |
Collapse
|
41
|
Abstract
Increased cerebrovascular permeability is an important factor for the development of cerebral edema. To investigate the effect of hypoxia on the transport of blood-borne proteins to the brain, we used a cell culture model of the blood-brain barrier (BBB) consisting of a coculture of brain capillary endothelial cells and astrocytes that closely mimics the in vivo situation. The permeability of albumin, a marker of the nonspecific transcellular route, is extremely low in this in vitro model of the BBB. After hypoxia, a huge increase in the permeability of albumin is detected. Despite the opening of the tight junctions already demonstrated after hypoxia, the increase in the permeability of albumin is mainly attributed to an increase of the non-specific vesicular transport in the cell, attested by the temperature dependence of the phenomenon and the visualization of labeled apotransferrin in the cytoplasm. The increase of this pathway could participate in the development of brain edema during hypoxia.
Collapse
Affiliation(s)
- M Plateel
- INSERM U. 325-SERLIA, Institut Pasteur de Lille, France
| | | | | |
Collapse
|
42
|
Ferrero JM, Namer M, Dufour JF, Largillier R, Creisson A, Teissier E, Machiavello JC, Lallement M, Monticelli J, Abbes M. [A comparative study of 4 sequential first-line chemotherapy protocols in locally advanced breast cancer]. Bull Cancer 1997; 84:10-6. [PMID: 9180853] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
Between 1977 and 1994, our center administered successively 4 different chemotherapy regimens to 242 evaluable patients with locally advanced breast cancer. Patients with inflammatory signs were excluded. Sixty-eight patients were treated by AVCF (A (adriamycine) + V (vincristine) + C (cytoxan) + F (5FU)), 47 by AECF (A + E (vindesine) + C + F), 81 by CAFP (C + A + F + P (prednisone)) and 46 by AN (A + N (vinorelbine)). The mean number of cycle was 3. One hundred and twenty-five patients (52.5%) responded to chemotherapy and we recorded 35 complete response (14.7%). The response rates at the different combinations were respectively: AVCF: 29.4%, AECF: 53.2%, CAFP: 64.9%, AN: 65.2%, and were independent of tumor size, grade and receptor status. The response rate at the AVCF regimen was significantly worse than the others (p = 0.0005). Breast conserving surgery was performed in 31 patients (14%) and 17 patients (8%) had a complete response. Among the 35 patients with complete response, 21 were treated by radiotherapy alone. Local recurrence occurred in 19 patients (7.9%) and 96 (40%) had advanced disease. The mean follow-up of AVCF regimen was 150 months, 115 months for AECF, 111 for CAFP and 42 months for AN. The disease-free survival and the overall survival were significantly better with AECF, CAFP and AN regimens (DFS p < 0.04, OS p < 0.02). Survival was better in those patients with an objective response (p = 0.002) or with non-affected axillary node at the time of surgery. Our study showed already that AVCF combination was significantly lower than AECF, CAFP, AN in terms of response rate, disease-free survival and overall survival. Waiting the results of randomized studies about the impact of neoadjuvant chemotherapy on survival, we look for chemotherapy regimen improving the rate of conservative surgery.
Collapse
Affiliation(s)
- J M Ferrero
- Service d'oncologie médicale, Centre Antoine-Lacassagne, Nice, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Cutuli B, Dilhuydy JM, De Lafontan B, Berlie J, Lacroze M, Lesaunier F, Graic Y, Tortochaux J, Resbeut M, Lesimple T, Gamelin E, Campana F, Reme-Saumon M, Moncho-Bernier V, Cuilliere JC, Marchal C, De Gislain G, N'Guyen TD, Teissier E, Velten M. Ductal carcinoma in situ of the male breast. Analysis of 31 cases. Eur J Cancer 1997; 33:35-8. [PMID: 9071896 DOI: 10.1016/s0959-8049(96)00436-4] [Citation(s) in RCA: 73] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
From 1970 to 1992, 31 pure ductal carcinoma in situ (DCIS) of the male breast treated in 19 French Regional Cancer Centres were reviewed. They represent 5% of all breast cancers treated in men in the same period. The median age was 58 years, but 6 patients were younger than 40 years. TNM classification (UICC, 1978) showed 12 T0 (discovered only by bloody nipple discharge), 10 T1, 5 T2 and four unclassified tumours (Tx). 11 patients (35.5%) had clinical gynecomastia, and three (10%) had a family history of breast cancer. 6 patients underwent lumpectomy, and 25 mastectomy. Axillary dissection was performed in 19 cases. 6 cases received postoperative irradiation. 15 out of 31 lesions were of the papillary subtype, pure or associated with a cribriform component. The size of the 12 measured lesions varied from 3 to 45 mm. All lymph nodes sampled were negative. With a median follow-up of 83 months, 4 patients (13%) presented a local relapse (LR), respectively, at 12, 27, 36 and 55 months. 3 of these patients had been initially treated by lumpectomy. In one case LR was still in situ, but already infiltrating in the 3 others. Radical salvage surgery was performed in 3 cases, but one patient developed metastases and died 30 months later. The last patient was treated by multiple local excisions and tamoxifen. One 43-year-old patient developed a contralateral DCIS and three others developed a metachronous cancer. The aetiology and risk factors of male breast cancer remain unknown. Gynecomastia, which implies an imbalance between androgen and oestrogen, may be a predisposing factor. As in women, DCIS in the male breast has a good prognosis. Total mastectomy without axillary dissection is the basic treatment. Frequently, the first symptom is a bloody nipple discharge. The age of occurrence is younger than for infiltrating carcinoma, suggesting that DCIS is the first step in the development of breast cancer.
Collapse
Affiliation(s)
- B Cutuli
- Centre Paul Strauss, Strasbourg, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Namer M, Ettore R, Pivot X, Ferrero JM, Teissier E. [Value of neo-angiogenesis evaluation in cancer of the breast]. Bull Cancer 1996; 83:1041-2. [PMID: 9116372] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Affiliation(s)
- M Namer
- Centre Antoine-Lacassagne, Nice, France
| | | | | | | | | |
Collapse
|
45
|
Garcion E, Thanh XD, Bled F, Teissier E, Dehouck MP, Rigault F, Brachet P, Girault A, Torpier G, Darcy F. 1,25-Dihydroxyvitamin D3 regulates gamma 1 transpeptidase activity in rat brain. Neurosci Lett 1996; 216:183-6. [PMID: 8897488 DOI: 10.1016/0304-3940(96)87802-5] [Citation(s) in RCA: 42] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
gamma-Glutamyl transpeptidase (gamma-GT), primarily described as a kidney enzyme, is also expressed in several cell types of the central nervous system (CNS). It is involved in the glutathione cycle and in cysteine transport. Here we report that the specific activity of this enzyme is transiently increased in the rat brain, following a treatment with 1,25-dihydroxyvitamin D3 (1,25-D3), the active form of vitamin D. In vitro experiments showed that this positive regulatory effect does not affect endothelial cells of the brain microvessels, but does affect pericytes and parenchymal astrocytes. Changes in the specific activity of gamma-GT were not correlated with any important modification of brain amino acid concentrations. Since gamma-GT is though to participate in the scavenging of reactive oxygen species, these data suggest that 1,25-D3 could be an effector controlling detoxification processes in the brain.
Collapse
|
46
|
Teissier E, Walters-Laporte E, Duhem C, Luc G, Fruchart JC, Duriez P. Rapid quantification of alpha-tocopherol in plasma and low- and high-density lipoproteins. Clin Chem 1996. [DOI: 10.1093/clinchem/42.3.430] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Abstract
Abstract
We have developed two methods for measuring the alpha-tocopherol content in plasma and lipoproteins (LDL and HDL). In procedure 1, plasma or lipoproteins are deproteinized with ethanol containing delta-tocopherol as internal standard and then extracted with hexane or ethyl acetate. The organic layer is removed and evaporated, and the residue is redissolved in methanol and injected into a reversed-phase HPLC. In procedure 2, plasma or lipoproteins are diluted in a methanol and ethanol mixture containing the same internal standard. The solution is vortex-mixed, centrifuged, and directly injected into the column. The tocopherols are eluted with an isocratic methanol mobile phase at a flow rate of 1 mL/min and detected by fluorescence (lambda(exc)= 295 nm, lambda(em)= 330nm). Recoveries are approximately 100% in both cases. Between-run CVs were 8.39% for procedure 1 and 6.55% for procedure 2. Small sample requirement, simplicity of sample preparation, short assay time, and good reproducibility make procedure 2 ideal for clinical or research use. This method was applied to determination of alpha-tocopherol in plasma of patients whose diet was supplemented with alpha-tocopherol and in LDL and HDL.
Collapse
Affiliation(s)
- E Teissier
- SERLIA et INSERM, Institut Pasteur, Lille, France
| | | | - C Duhem
- SERLIA et INSERM, Institut Pasteur, Lille, France
| | - G Luc
- SERLIA et INSERM, Institut Pasteur, Lille, France
| | - J C Fruchart
- SERLIA et INSERM, Institut Pasteur, Lille, France
| | - P Duriez
- SERLIA et INSERM, Institut Pasteur, Lille, France
| |
Collapse
|
47
|
Teissier E, Walters-Laporte E, Duhem C, Luc G, Fruchart JC, Duriez P. Rapid quantification of alpha-tocopherol in plasma and low- and high-density lipoproteins. Clin Chem 1996; 42:430-5. [PMID: 8598108] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
We have developed two methods for measuring the alpha-tocopherol content in plasma and lipoproteins (LDL and HDL). In procedure 1, plasma or lipoproteins are deproteinized with ethanol containing delta-tocopherol as internal standard and then extracted with hexane or ethyl acetate. The organic layer is removed and evaporated, and the residue is redissolved in methanol and injected into a reversed-phase HPLC. In procedure 2, plasma or lipoproteins are diluted in a methanol and ethanol mixture containing the same internal standard. The solution is vortex-mixed, centrifuged, and directly injected into the column. The tocopherols are eluted with an isocratic methanol mobile phase at a flow rate of 1 mL/min and detected by fluorescence (lambda(exc)= 295 nm, lambda(em)= 330nm). Recoveries are approximately 100% in both cases. Between-run CVs were 8.39% for procedure 1 and 6.55% for procedure 2. Small sample requirement, simplicity of sample preparation, short assay time, and good reproducibility make procedure 2 ideal for clinical or research use. This method was applied to determination of alpha-tocopherol in plasma of patients whose diet was supplemented with alpha-tocopherol and in LDL and HDL.
Collapse
Affiliation(s)
- E Teissier
- SERLIA et INSERM, Institut Pasteur, Lille, France
| | | | | | | | | | | |
Collapse
|
48
|
Chauvel P, Iborra-Brassart N, Courdi A, Hérault J, Teissier E, Pignol JP, Bondiau PY. Proton therapy in ophthalmology: status report and problems encountered. Bull Cancer Radiother 1996; 83 Suppl:215s-8s. [PMID: 8949783 DOI: 10.1016/0924-4212(96)84916-4] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
The proton therapy facility of the Centre Antoine-Lacassagne in Nice began treatment of ocular tumors in June 1991. Up to October 1995, a total number of 600 patients were treated. An overview of the cases treated during the first 4 years of activity is given and the main problems encountered in the field, possibly interacting with the accuracy and reliability of the dose distribution, are listed.
Collapse
Affiliation(s)
- P Chauvel
- Centre Antoine-Lacassagne CAL, Cyclotron Biomédical, Nice, France
| | | | | | | | | | | | | |
Collapse
|
49
|
Lagrange J, Granon C, Teissier E, Gioanni J, Bensadoun R, Courdi A, Birtwisle Peyrottes I, Ettore F. 219Uterine cervix carcinoma: Value of labelling index in stage I and II. Radiother Oncol 1996. [DOI: 10.1016/s0167-8140(96)80228-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
50
|
De Lafonten B, Resbeut M, Teissier E, Hery M, Cutuli B, Marchal C, Achard J, Campana F, Nguyen T, Dilhuydy J, Gindrey B, Mihura J. PP-3-6 Patterns of Diagnosis of 350 Breast Failures in Patients Treated with Conservative Breast surgery, axillary dissection and RT for Breast Cancer. Eur J Cancer 1996. [DOI: 10.1016/0959-8049(96)84097-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|